12 Best Performing Biotech Stocks in 2023

Published on October 20, 2023 at 1:22 pm by Ramish Cheema in Hedge Funds, News

In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Best Performing Biotech Stocks in 2023.

Biotechnology is one of the hottest industries these days and one that has risen to prominence after the outbreak of the coronavirus pandemic. The world’s response to the pandemic revolved around mRNA vaccines, which were developed using breakthrough technologies that had previously been used to develop cancer vaccines.

Biotechnology refers to products that rely on natural raw materials that are sourced from biological sources. This ability to use novel materials allows the industry to target some of the most serious diseases known to humankind such as cancer. At the same time, biotechnology also allows researchers and firms to target plant and animal health as well.

The interest in the sector after the pandemic has seen vast amounts of capital flow into the biotechnology industry. Research from the consultancy firm McKinsey shows that between 2019 and 2021, venture capital firms plowed in $52 billion in biotechnology companies, which marked an increase not only in dollar terms but also in the number of companies that were invested in. McKinsey’s data shows that during 2016, VC firms had invested in 2,200 biotechnology startups and this number jumped to 3,100 firms by 2021. Similarly, biotechnology firms had raised $34 billion in 2021, which was nearly twice the funding in 2020 that had sat at $16 billion.

Just like the broader consumer technology sector, the biotechnology industry is divided into several categories as well. These include cell therapy firms, those developing precision medicines, cancer treatment providers, and firms that leverage machine learning to develop new drugs among others. For the venture capitalists, the largest share of their investment flows during 2019 and 2021, $7.7 billion and $7.6 billion were invested into cell therapy firms and those developing next generation genetic therapies. Gene therapies and the broader genomics industry are also some of the hottest medical sectors these days. If you’re interested in such firms, then we took a look at the 12 Gene Editing Stocks With the Best Long-Term Potential and found that the top three firms were Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Agilent Technologies, Inc. (NYSE:A), and Exact Sciences Corporation (NASDAQ:EXAS).

However, while we’ve focused on the consumer end of biotechnology and some such stocks so far, there is also an industrial biotechnology sector. This sector involves using biological products to produce chemicals, fuels, and other raw materials and end products that are used by industrial users. For instance, biofuels are quite hot among airlines and other organizations these days due to their ability to reduce greenhouse gas emissions. In fact, estimates from the Department of Energy show that the U.S. can reduce its gasoline consumption by as much as 30% if it uses biomass feed stocks to produce ethanol. We also took a look at 10 Best Biofuel Stocks To Buy Now, and among these, the top three picks are NewMarket Corporation (NYSE:NEU), Green Plains Inc. (NASDAQ:GPRE), and KBR, Inc. (NYSE:KBR).

Delving deeper into the industrial biotechnology sector, research from FESTEL Capital shares quite a bit of details that have to be considered when investing in this space. It outlines that industrial biotechnology firms often face difficulties in raising capital when the global economy is in turmoil as venture capital firms are unable to easily raise capital. It adds that operating income is often the biggest source of financing for industrial biotechnology companies and that within the sector, agrochemical and pharmaceutical companies are among the most confident when making investments into new plants due to short term demand for their products.

Finally, before we head to the best performing biotech stocks in 2023, it’s also important to look at the biggest developments in the industry this year. One of the biggest biotechnology developments in 2023 came from researchers at the State University of New York who developed a new strain of the E. Coli bacteria that is capable of producing biodegradable plastics that are environmentally friendly. Another key development came from the University of Pennsylvania where researchers were able to increase the number of root hairs in a plant’s roots to increase their surface area to absorb water and nutrients from the soil.

With these details in mind, let’s take a look at the top performing biotech stocks in 2023, with the notable ones being MoonLake Immunotherapeutics (NASDAQ:MLTX), Soleno Therapeutics, Inc. (NASDAQ:SLNO), and Tempest Therapeutics, Inc. (NASDAQ:TPST).

Photo by National Cancer Institute on Unsplash

Our Methodology

For our list of the best performing biotech stocks in 2023, we ranked all biotechnology companies by their year to date share price performance and picked the top performing stocks.

Best Performing Biotech Stocks in 2023

12. ImmunoGen, Inc. (NASDAQ:IMGN)

Year To Date Share Price Gains: 205.77%

ImmunoGen, Inc. (NASDAQ:IMGN) is a pure play cancer treatment company with several products in clinical trials. Its shares are rated Strong Buy on average, with JPMorgan upgrading its share rating to Overweight and Hold in September 2023.

Out of the 910 hedge funds tracked by Insider Monkey for their Q2 2023 shareholdings, 42 had held a stake in the company. ImmunoGen, Inc. (NASDAQ:IMGN)’s biggest hedge fund investor is Jeremy Green’s Redmile Group due to its $334 million stake.

Along with Soleno Therapeutics, Inc. (NASDAQ:SLNO), MoonLake Immunotherapeutics (NASDAQ:MLTX), and Tempest Therapeutics, Inc. (NASDAQ:TPST), ImmunoGen, Inc. (NASDAQ:IMGN) is a top performing biotech stock in 2023.

11. Renovaro Biosciences Inc. (NASDAQ:RENB)

Year To Date Share Price Gains: 210.62%

Renovaro Biosciences Inc. (NASDAQ:RENB) is a small biotechnology company that is developing treatments for one of the most serious diseases known to humankind, HIV. In a shareholder letter issued in October 2023, its CEO shared that its AI division plans to introduce new cancer products in 2024.

Two hedge funds out of the 910 polled by Insider Monkey were Renovaro Biosciences Inc. (NASDAQ:RENB)’s investors as of June 2023. Israel Englander’s Millennium Management is the largest shareholder out of these, owning 251,478 shares that are worth $142,487.

10. Genelux Corporation (NASDAQ:GNLX)

Year To Date Share Price Gains: 227.48%

Genelux Corporation (NASDAQ:GNLX) is a California based biotechnology firm that develops treatments for pancreatic, ovarian, and lung cancer. Its shares are rated Buy on average and analysts have set an average share price target of $34.33. The firm’s second quarter results saw it outline $27.1 million cash in hand, which, along with other holdings, should be sufficient to cover operations by 2026 according to management.

9. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Year To Date Share Price Gains: 230.82%

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) is another small biotech firm. It is researching treatments for diseases that hamper the human cells’ abilities to produce energy. The firm scored a win in June 2023 when it was added to the Russell 2000 stock index.

By the end of this year’s June quarter, nine out of the 910 hedge funds provided by Insider Monkey had bought and owned Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)’s shares. Ting Jia’s Octagon Capital Advisors is the largest stakeholder out of these through its $15.5 million investment.

8. Applied Therapeutics, Inc. (NASDAQ:APLT)

Year To Date Share Price Gains: 237.15%

Applied Therapeutics, Inc. (NASDAQ:APLT) develops treatments for patients with diabetes and nervous system disorders. The firm announced in September 2023 that it has filed a new application with the FDA for a disease that hampers the human body’s ability to produce glucose.

As of June 2023, nine out of the 910 hedge funds tracked by Insider Monkey had held a stake in the firm. Applied Therapeutics, Inc. (NASDAQ:APLT)’s biggest hedge fund investor is Anand Parekh’s Alyeska Investment Group as it owns $5.6 million worth of shares.

7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Year To Date Share Price Gains: 255.51%

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is an American biotechnology company headquartered in Palo Alto, California. The firm focuses its efforts on developing treatments for genetic diseases of the cardiovascular system, the renal system, and others. Its shares are rated Strong Buy on average and analysts have set an average price target of $46.40.

During Q2 2023, 32 out of the 910 hedge funds profiled by Insider Monkey held a stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO). Out of these, the firm’s largest shareholder is Andreas Halvorsen’s Viking Global since it owns 26.6 million shares that are worth $457 million.

6. Minerva Neurosciences, Inc. (NASDAQ:NERV)

Year To Date Share Price Gains: 276.78%

Minerva Neurosciences, Inc. (NASDAQ:NERV) is a specialized biotech firm that is developing treatments for nervous system disorders. The firm’s second quarter results saw it report $51.9 million in cash and $1.9 million in quarterly research and development spending.

Only one hedge fund among the 910 tracked by Insider Monkey had invested in the firm as of June 2023. This lone Minerva Neurosciences, Inc. (NASDAQ:NERV) investor is Jim Simons’ Renaissance Technologies due to its $898,000 investment.

MoonLake Immunotherapeutics (NASDAQ:MLTX), Minerva Neurosciences, Inc. (NASDAQ:NERV), Soleno Therapeutics, Inc. (NASDAQ:SLNO), and Tempest Therapeutics, Inc. (NASDAQ:TPST) are some of 2023’s best performing biotech stocks.

Click here to continue reading and check out 5 Best Performing Biotech Stocks in 2023.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on October 6, 2025 at by Inan Dogan, PhD

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on October 5, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

12 Best Performing Biotech Stocks in 2023

Published on October 20, 2023 at 1:22 pm by Ramish Cheema in Hedge Funds, News

Best Performing Biotech Stocks in 2023

12. ImmunoGen, Inc. (NASDAQ:IMGN)

11. Renovaro Biosciences Inc. (NASDAQ:RENB)

10. Genelux Corporation (NASDAQ:GNLX)

9. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

8. Applied Therapeutics, Inc. (NASDAQ:APLT)

7. BridgeBio Pharma, Inc. (NASDAQ:BBIO)

6. Minerva Neurosciences, Inc. (NASDAQ:NERV)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on October 6, 2025 at by Inan Dogan, PhD

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on October 5, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: